A Phase 3 interventional study of Mirikizumab SC and Mirikizumab IV in Ulcerative Colitis, sponsored by Eli Lilly and Company. Completed at 385 sites in 34 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-05-13.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing mirikizumab in Colitis, Ulcerative — 4 open to participants now, 5 under way, 2 of them phase 3. mirikizumab · Colitis, Ulcerative.
Among the 13 studies testing mirikizumab in Colitis, Ulcerative, this one has the largest enrollment, is one of 3 that started in 2018, is one of 7 in phase 3, and was the 4th registered.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →4 of the 13 studies testing mirikizumab in Colitis, Ulcerative are open now, in 12 countries. Recruiting first, the newest first:
University Hospital Schleswig-Holstein · Sites in Germany
Ages 18–75
Eli Lilly and Company · Sites in United States, Austria, Belgium and 13 more countries
Ages 2–19
Specialty Networks Research. · Sites in United States
Ages 21+
Rubix LS · Sites in United States
Ages 60–99
By country, each count listing its studies:
mirikizumab: first FDA approval 2023 (OMVOH), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 3 started in 2018.
This study's enrollment of 1,328 is above the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 172 across the 13 interventional studies. Of the 7 that completed or were terminated, 5 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 13 have an industry lead sponsor. The 5 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
16 studies in Colitis, Ulcerative by Eli Lilly and Company: 5 open now, 7 under way, 3 of them phase 3. Of 8 finished, 7 (88%) have results posted.
Among the 16 studies in Colitis, Ulcerative by Eli Lilly and Company, this one is the 2nd largest by enrollment, is one of 3 that started in 2018, is one of 8 in phase 3, and was the 4th registered.
Eli Lilly and Company’s Colitis, Ulcerative studies by the year they started, since 2015.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing mirikizumab in Colitis, Ulcerative, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 16 in Colitis, Ulcerative:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of mirikizumab as maintenance therapy in participants who completed as clinical responders in the prior 12-week induction study LUCENT-1 (NCT03518086).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who were responders to blinded mirikizumab (miri) at Week 12 in induction study (LUCENT-1) randomized to withdraw from mirikizumab and start receiving PBO SC every 4 weeks (Q4W) from Week 0 of maintenance study (LUCENT-2) until Week 40 or until loss of response was confirmed.
Drug: Placebo SC
Participants who were responders to blinded mirikizumab at Week 12 in induction study (LUCENT-1) randomized to continue to receive 200 mg mirikizumab SC Q4W from Week 0 of LUCENT-2 until Week 40 or until loss of response was confirmed.
Drug: Mirikizumab SC
Participants who were responders to blinded placebo at Week 12 in induction study (LUCENT-1) continue to receive blinded placebo SC Q4W from Week 0 of LUCENT-2 until Week 40 or until loss of response was confirmed.
Drug: Placebo SC
Participants in the ME2 Cohort who were responders to blinded mirikizumab (miri) at Week 12 in induction study (LUCENT-1) randomized to withdraw from mirikizumab and start receiving PBO SC every 4 weeks (Q4W) from Week 0 of maintenance study (LUCENT-2) until Week 40 or until loss of response was confirmed.
Drug: Placebo SC
Participants in the ME2 Cohort who were responders to blinded mirikizumab at Week 12 in induction study (LUCENT-1) randomized to continue to receive 200 mg mirikizumab SC Q4W from Week 0 of LUCENT-2 until Week 40 or until loss of response was confirmed.
Drug: Mirikizumab SC
Participants in the ME2 Cohort who were responders to blinded placebo at Week 12 in induction study (LUCENT-1) continue to receive blinded placebo SC Q4W from Week 0 of LUCENT-2 until Week 40 or until loss of response was confirmed.
Drug: Mirikizumab IV · Drug: Placebo SC
Participants who received blinded PBO SC or blinded 200 mg mirikizumab SC Q4W during maintenance period and experienced a loss of response at or after Week 12, received rescue therapy with open label 300 mg mirikizumab intravenous (IV) Q4W for 3 doses.
Drug: Mirikizumab IV
Participants in the ME2 Cohort who received blinded PBO SC or blinded 200 mg mirikizumab SC Q4W during maintenance period and experienced a loss of response at or after Week 12, received rescue therapy with open label 300 mg mirikizumab intravenous (IV) Q4W for 3 doses.
Drug: Mirikizumab IV
Participants who were nonresponders to blinded mirikizumab or placebo in induction study (LUCENT-1), received additional 3 doses of open label 300 mg mirikizumab IV Q4W during extended induction period from Week 0 of LUCENT-2 until Week 12.
Drug: Mirikizumab IV
Participants in the ME2 Cohort who were nonresponders to blinded mirikizumab or placebo in induction study (LUCENT-1), received additional 3 doses of open label 300 mg mirikizumab IV Q4W during extended induction period from Week 0 of LUCENT-2 until Week 12.
Drug: Mirikizumab IV
Participants who initially did not respond to induction study (LUCENT-1), but responded to extended induction therapy at Week 12 of LUCENT-2 (delayed responders), received 200 mg mirikizumab SC Q4W during open label maintenance period from Week 12 until Week 40 or until early termination (rescue was not available for these participants).
Drug: Mirikizumab SC
Participants in the ME2 Cohort who initially did not respond to induction study (LUCENT-1), but responded to extended induction therapy at Week 12 of LUCENT-2 (delayed responders), received 200 mg mirikizumab SC Q4W during open label maintenance period from Week 12 until Week 40 or until early termination (rescue was not available for these participants).
Drug: Mirikizumab SC
Administered SC
Also known as: LY3074828
Administered IV
Also known as: LY3074828
Administered SC
Percentage of Participants in Clinical Remission at Week 40 (Mirikizumab Induction Responders)
Clinical remission at week 40 is defined as achieving a 9-point modified Mayo score for rectal bleeding=0, stool frequency=0 or 1 with ≥ 1 point decrease from baseline, and endoscopy=0 or 1 (excluding friability). Stool Frequency Subscore, based on the participant's diary and scored from 0 (normal number of stools) to 3 (5 or more stools than normal); Rectal Bleeding Subscore, based on the participant's diary and scored from 0 (no blood) to 3 (blood only passed); Endoscopy Subscore, based on central reading of colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration). Modified Intention-to-treat population (mITT): All randomized participants who received at least one dose of mirikizumab and who had a correctly measured Modified Mayo Score at baseline. Participants were analyzed according to the treatment arm to which they were randomized, regardless of the treatment actually received.
Time frame: Week 40
Percentage of Participants in Endoscopic Remission at Week 40 (Mirikizumab Induction Responders)
Endoscopic remission at week 40 is defined as achieving a Mayo endoscopic subscore of 0 or 1 (excluding friability) at Week 40. Endoscopy subscore is based on colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration).
Time frame: Week 40
Percentage of Participants With Histologic Remission at Week 40 (Mirikizumab Induction Responders)
Histologic remission was assessed using the Geboes histologic scoring system developed for assessment of histologic disease activity in ulcerative colitis. Remission was defined as Geboes histological subscore of 0 for grades: 2b (lamina propria neutrophils), and 3 (neutrophils in epithelium), and 4 (crypt destruction), and 5 (erosion or ulceration).
Time frame: Week 40
Percentage of Participants in Symptomatic Remission at Week 40 (Mirikizumab Induction Responders)
Symptomatic remission at week 40 is defined as a Mayo score for rectal bleeding=0, stool frequency=0 or 1 with ≥ 1 point decrease from baseline. Stool frequency subscore, based on the participant's diary and scored from 0 (normal number of stools) to 3 (5 or more stools than normal). Rectal bleeding subscore, based on the participant's diary and scored from 0 (no blood seen) to 3 (blood alone passed).
Time frame: Week 40
Percentage of Participants in Endoscopic Response at Week 40 (Mirikizumab Induction Responders)
Endoscopic response at week 40 is defined as achieving at least a 1 point decrease from baseline in the Mayo endoscopic subscore.
Time frame: Week 40
Percentage of Participants in Clinical Response at Week 40 (Mirikizumab Induction Responders)
Clinical response at week 40 is defined as a decrease in the 9-point modified Mayo score (MMS) \[rectal bleeding, stool frequency and the endoscopic findings\] inclusive of \>= 2 points and \>=30% from baseline with either a decrease of rectal bleeding subscore of \>=1 or rectal bleeding subscore of 0 or 1.The MMS is a composite score of ulcerative colitis disease activity calculated as the sum of three subscores: Stool frequency subscore, based on the participant's diary and scored from 0 (normal number of stools) to 3 (5 or more stools than normal); Rectal bleeding subscore, based on the participant's diary and scored from 0 (no blood seen) to 3 (blood alone passed); Endoscopy subscore, based on colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding,ulceration).
Time frame: Week 40
Change From Baseline to Week 40 in Health Related Quality of Life: Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score (Mirikizumab Induction Responders)
The IBDQ is a 32-item participant-completed questionnaire that measures 4 aspects of subjects' lives: symptoms directly related to the primary bowel disturbance, systemic symptoms, emotional function, and social function. Responses are graded on a 7-point. Likert scale in which 7 denotes "not a problem at all" and 1 denotes "a very severe problem." Scores range from 32 to 224; a higher score indicates a better quality of life. Least square (LS) Mean was calculated using analysis of covariance (ANCOVA) model for post-baseline measures: The ANCOVA model includes: treatment, baseline value, prior biologic or tofacitinib failure (yes/no), clinical remission status (yes/no) at AMAN Week 12, and region (North America/Europe/Other).
Time frame: Induction Baseline, Week 40
Change From Baseline to Week 40 in Fecal Calprotectin (Mirikizumab Induction Responders)
Fecal calprotectin is an indicator of inflammation in the colon with higher levels indicative of higher levels of inflammation. Least square (LS) Mean was calculated using ANCOVA model for post-baseline measures: The ANCOVA model includes treatment, baseline value, prior biologic or tofacitinib failure (yes/no), corticosteroid use (yes/no) at AMAN baseline, region (North America/Europe/Other), Clinical Remission status (yes/no) at AMAN Week 12.
Time frame: Induction Baseline, Week 40
Change From Baseline to Week 40 in Bowel Urgency Based on the Urgency Numeric Rating Scale (NRS) (Mirikizumab Induction Responders)
The Urgency NRS is a single participant reported item that measures the severity for the urgency (sudden or immediate need) to have a bowel movement in the past 24 hours using an 11-point NRS ranging from 0 (no urgency) to 10 (worst possible urgency). Higher scores indicate more severe urgency. Least square (LS) Mean was calculated using mixed model repeated measures (MMRM) model for post-baseline measures: The MMRM model includes treatment, baseline value, visit, interaction of baseline value-by-visit, interaction of treatment-by-visit, prior biologic or tofacitinib failure (yes/no), baseline corticosteroid use (yes/no), clinical remission status (yes/no) at AMAN Week 12, and region (North America/Europe/Other).
Time frame: Induction Baseline, Week 40
Percentage of Participants Hospitalized for Ulcerative Colitis (UC) (Mirikizumab Induction Responders)
Percentage of participants hospitalized for UC. Only hospitalizations associated with an adverse event with \>=24 hours stay were recorded.
Time frame: Week 40
Pharmacokinetics (PK): Clearance of Mirikizumab
Clearance of mirikizumab was evaluated.
Time frame: Predose: Weeks 0, 4, 12, 24 and 40
A total of 1177 Participants (pts) enrolled in study of which 716 pts entered to Blinded Maintenance Period as Induction Responder (IR) and 461 pts entered into open label extended Induction period as Induction Nonresponders. This LUCENT-2 (I6T-MC-AMBG, NCT03524092) study was designed to evaluate safety and efficacy of mirikizumab (miri) in achieving remission at Week (Wk) 40 in pts who completed the 12-wk induction study LUCENT-1 (I6T-MC-AMAN,NCT03518086) as clinical responders to mirikizumab.
| Milestone | Maintenance Period: Miri IR - Placebo (PBO) Subcutaneous (SC) | Maintenance Period: Miri IR - 200 Milligram (mg) Miri SC | Maintenance Period: PBO IR - PBO SC | Maintenance Period: Miri IR - PBO SC - ME2 Cohort | Maintenance Period: Miri IR - 200 mg Miri SC - ME2 Cohort | Maintenance Period: PBO IR - PBO SC - ME2 Cohort | Loss of Response (LOR) Rescue Period:LOR Cohort-300 mg Miri IV | LOR Rescue Period:LOR Cohort-300 mg Miri IV - ME2 Cohort | Extended Induction: Induction Nonresponders - 300mg Miri IV | Extended Induction: Induction Nonresponders - 300mg Miri IV - ME2 Cohort | Open Label Maintenance: Delayed Responders - 200 mg Miri SC | Open Label Maintenance: Delayed Responders - 200 mg Miri SC - ME2 Cohort |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 192 | 389 | 135 | 21 | 52 | 12 | 0 | 0 | 0 | 0 | 0 | 0 |
| Received at least one dose of study drug | 192 | 389 | 135 | 21 | 52 | 12 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 119 | 347 | 90 | 12 | 46 | 8 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 73 | 42 | 45 | 9 | 6 | 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 16 | 6 | 1 | 2 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 8 | 6 | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Pregnancy | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 7 | 8 | 6 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Loss of response rescue period | 42 | 19 | 29 | 6 | 2 | 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Maintenance Period: Miri IR - Placebo (PBO) Subcutaneous (SC) | Maintenance Period: Miri IR - 200 Milligram (mg) Miri SC | Maintenance Period: PBO IR - PBO SC | Maintenance Period: Miri IR - PBO SC - ME2 Cohort | Maintenance Period: Miri IR - 200 mg Miri SC - ME2 Cohort | Maintenance Period: PBO IR - PBO SC - ME2 Cohort | Loss of Response (LOR) Rescue Period:LOR Cohort-300 mg Miri IV | LOR Rescue Period:LOR Cohort-300 mg Miri IV - ME2 Cohort | Extended Induction: Induction Nonresponders - 300mg Miri IV | Extended Induction: Induction Nonresponders - 300mg Miri IV - ME2 Cohort | Open Label Maintenance: Delayed Responders - 200 mg Miri SC | Open Label Maintenance: Delayed Responders - 200 mg Miri SC - ME2 Cohort |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 90 | 12 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 81 | 9 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 9 | 3 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Completed rescue treatment and rolled over to study i6t-mc-amap (nct03519945) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| Milestone | Maintenance Period: Miri IR - Placebo (PBO) Subcutaneous (SC) | Maintenance Period: Miri IR - 200 Milligram (mg) Miri SC | Maintenance Period: PBO IR - PBO SC | Maintenance Period: Miri IR - PBO SC - ME2 Cohort | Maintenance Period: Miri IR - 200 mg Miri SC - ME2 Cohort | Maintenance Period: PBO IR - PBO SC - ME2 Cohort | Loss of Response (LOR) Rescue Period:LOR Cohort-300 mg Miri IV | LOR Rescue Period:LOR Cohort-300 mg Miri IV - ME2 Cohort | Extended Induction: Induction Nonresponders - 300mg Miri IV | Extended Induction: Induction Nonresponders - 300mg Miri IV - ME2 Cohort | Open Label Maintenance: Delayed Responders - 200 mg Miri SC | Open Label Maintenance: Delayed Responders - 200 mg Miri SC - ME2 Cohort |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 461 | 66 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 271 | 33 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 190 | 33 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11 | 1 | 0 | 0 |
| Withdrew: Covid-19 related study disruption | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 162 | 26 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 5 | 0 | 0 |
| Withdrew: Lack of capacity due to lack of staff | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Milestone | Maintenance Period: Miri IR - Placebo (PBO) Subcutaneous (SC) | Maintenance Period: Miri IR - 200 Milligram (mg) Miri SC | Maintenance Period: PBO IR - PBO SC | Maintenance Period: Miri IR - PBO SC - ME2 Cohort | Maintenance Period: Miri IR - 200 mg Miri SC - ME2 Cohort | Maintenance Period: PBO IR - PBO SC - ME2 Cohort | Loss of Response (LOR) Rescue Period:LOR Cohort-300 mg Miri IV | LOR Rescue Period:LOR Cohort-300 mg Miri IV - ME2 Cohort | Extended Induction: Induction Nonresponders - 300mg Miri IV | Extended Induction: Induction Nonresponders - 300mg Miri IV - ME2 Cohort | Open Label Maintenance: Delayed Responders - 200 mg Miri SC | Open Label Maintenance: Delayed Responders - 200 mg Miri SC - ME2 Cohort |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 271 | 33 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 256 | 30 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 15 | 3 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 1 |
| Withdrew: Covid-19 related study disruption | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
Clinical remission at week 40 is defined as achieving a 9-point modified Mayo score for rectal bleeding=0, stool frequency=0 or 1 with ≥ 1 point decrease from baseline, and endoscopy=0 or 1 (excluding friability). Stool Frequency Subscore, based on the participant's diary and scored from 0 (normal number of stools) to 3 (5 or more stools than normal); Rectal Bleeding Subscore, based on the participant's diary and scored from 0 (no blood) to 3 (blood only passed); Endoscopy Subscore, based on central reading of colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration). Modified Intention-to-treat population (mITT): All randomized participants who received at least one dose of mirikizumab and who had a correctly measured Modified Mayo Score at baseline. Participants were analyzed according to the treatment arm to which they were randomized, regardless of the treatment actually received.
| percentage of participants | Maintenance Period: Miri IR - PBO SC | Maintenance Period: Miri IR - 200 mg Miri SC |
|---|---|---|
| Percentage of Participants in Clinical Remission at Week 40 (Mirikizumab Induction Responders) | 25.1 (18.8 to 31.5) | 49.9 (44.7 to 55.0) |
Endoscopic remission at week 40 is defined as achieving a Mayo endoscopic subscore of 0 or 1 (excluding friability) at Week 40. Endoscopy subscore is based on colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration).
| percentage of participants | Maintenance Period: Miri IR - PBO SC | Maintenance Period: Miri IR - 200 mg Miri SC |
|---|---|---|
| Percentage of Participants in Endoscopic Remission at Week 40 (Mirikizumab Induction Responders) | 29.1 (22.4 to 35.7) | 58.6 (53.6 to 63.7) |
Histologic remission was assessed using the Geboes histologic scoring system developed for assessment of histologic disease activity in ulcerative colitis. Remission was defined as Geboes histological subscore of 0 for grades: 2b (lamina propria neutrophils), and 3 (neutrophils in epithelium), and 4 (crypt destruction), and 5 (erosion or ulceration).
| percentage of participants | Maintenance Period: Miri IR - PBO SC | Maintenance Period: Miri IR - 200 mg Miri SC |
|---|---|---|
| Percentage of Participants With Histologic Remission at Week 40 (Mirikizumab Induction Responders) | 24.6 (18.3 to 30.9) | 48.5 (43.4 to 53.6) |
Symptomatic remission at week 40 is defined as a Mayo score for rectal bleeding=0, stool frequency=0 or 1 with ≥ 1 point decrease from baseline. Stool frequency subscore, based on the participant's diary and scored from 0 (normal number of stools) to 3 (5 or more stools than normal). Rectal bleeding subscore, based on the participant's diary and scored from 0 (no blood seen) to 3 (blood alone passed).
| percentage of participants | Maintenance Period: Miri IR - PBO SC | Maintenance Period: Miri IR - 200 mg Miri SC |
|---|---|---|
| Percentage of Participants in Symptomatic Remission at Week 40 (Mirikizumab Induction Responders) | 39.7 (32.5 to 46.8) | 71.0 (66.3 to 75.6) |
Endoscopic response at week 40 is defined as achieving at least a 1 point decrease from baseline in the Mayo endoscopic subscore.
| percentage of participants | Maintenance Period: Miri IR - PBO SC | Maintenance Period: Miri IR - 200 mg Miri SC |
|---|---|---|
| Percentage of Participants in Endoscopic Response at Week 40 (Mirikizumab Induction Responders) | 40.8 (33.6 to 48.0) | 72.6 (68.0 to 77.2) |
Clinical response at week 40 is defined as a decrease in the 9-point modified Mayo score (MMS) \[rectal bleeding, stool frequency and the endoscopic findings\] inclusive of \>= 2 points and \>=30% from baseline with either a decrease of rectal bleeding subscore of \>=1 or rectal bleeding subscore of 0 or 1.The MMS is a composite score of ulcerative colitis disease activity calculated as the sum of three subscores: Stool frequency subscore, based on the participant's diary and scored from 0 (normal number of stools) to 3 (5 or more stools than normal); Rectal bleeding subscore, based on the participant's diary and scored from 0 (no blood seen) to 3 (blood alone passed); Endoscopy subscore, based on colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding,ulceration).
| percentage of participants | Maintenance Period: Miri IR - PBO SC | Maintenance Period: Miri IR - 200 mg Miri SC |
|---|---|---|
| Percentage of Participants in Clinical Response at Week 40 (Mirikizumab Induction Responders) | 49.2 (41.8 to 56.5) | 80.3 (76.2 to 84.4) |
The IBDQ is a 32-item participant-completed questionnaire that measures 4 aspects of subjects' lives: symptoms directly related to the primary bowel disturbance, systemic symptoms, emotional function, and social function. Responses are graded on a 7-point. Likert scale in which 7 denotes "not a problem at all" and 1 denotes "a very severe problem." Scores range from 32 to 224; a higher score indicates a better quality of life. Least square (LS) Mean was calculated using analysis of covariance (ANCOVA) model for post-baseline measures: The ANCOVA model includes: treatment, baseline value, prior biologic or tofacitinib failure (yes/no), clinical remission status (yes/no) at AMAN Week 12, and region (North America/Europe/Other).
| score on a scale | Maintenance Period: Miri IR - PBO SC | Maintenance Period: Miri IR - 200 mg Miri SC |
|---|---|---|
| Change From Baseline to Week 40 in Health Related Quality of Life: Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score (Mirikizumab Induction Responders) | 24.51 ± 2.767 | 49.75 ± 2.102 |
Fecal calprotectin is an indicator of inflammation in the colon with higher levels indicative of higher levels of inflammation. Least square (LS) Mean was calculated using ANCOVA model for post-baseline measures: The ANCOVA model includes treatment, baseline value, prior biologic or tofacitinib failure (yes/no), corticosteroid use (yes/no) at AMAN baseline, region (North America/Europe/Other), Clinical Remission status (yes/no) at AMAN Week 12.
| milligram per kilogram (mg/kg) | Maintenance Period: Miri IR - PBO SC | Maintenance Period: Miri IR - 200 mg Miri SC |
|---|---|---|
| Change From Baseline to Week 40 in Fecal Calprotectin (Mirikizumab Induction Responders) | -1155.82 ± 221.394 | -1995.47 ± 172.443 |
The Urgency NRS is a single participant reported item that measures the severity for the urgency (sudden or immediate need) to have a bowel movement in the past 24 hours using an 11-point NRS ranging from 0 (no urgency) to 10 (worst possible urgency). Higher scores indicate more severe urgency. Least square (LS) Mean was calculated using mixed model repeated measures (MMRM) model for post-baseline measures: The MMRM model includes treatment, baseline value, visit, interaction of baseline value-by-visit, interaction of treatment-by-visit, prior biologic or tofacitinib failure (yes/no), baseline corticosteroid use (yes/no), clinical remission status (yes/no) at AMAN Week 12, and region (North America/Europe/Other).
| score on a scale | Maintenance Period: Miri IR - PBO SC | Maintenance Period: Miri IR - 200 mg Miri SC |
|---|---|---|
| Change From Baseline to Week 40 in Bowel Urgency Based on the Urgency Numeric Rating Scale (NRS) (Mirikizumab Induction Responders) | -2.74 ± 0.202 | -3.80 ± 0.139 |
Percentage of participants hospitalized for UC. Only hospitalizations associated with an adverse event with \>=24 hours stay were recorded.
| percentage of participants | Maintenance Period: Miri IR - PBO SC | Maintenance Period: Miri IR - 200 mg Miri SC |
|---|---|---|
| Percentage of Participants Hospitalized for Ulcerative Colitis (UC) (Mirikizumab Induction Responders) | 1.1 | 0 |
Clearance of mirikizumab was evaluated.
| Liters per Hour (L/h) | 200 Milligram (mg) Miri SC |
|---|---|
| Pharmacokinetics (PK): Clearance of Mirikizumab | 0.0487 ± 54 |
Collected over Baseline Up to week 56. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Maintenance Period: Miri IR - PBO SC | 1/192 (0.5%) | 16/192 (8.3%) | 82/192 (42.7%) |
| Maintenance Period: Miri IR - 200 mg Miri SC | 0/389 (0%) | 13/389 (3.3%) | 143/389 (36.8%) |
| Maintenance Period: PBO IR - PBO SC | 0/135 (0%) | 8/135 (5.9%) | 58/135 (43%) |
| Maintenance Period: Miri IR - PBO SC - ME2 Cohort | 0/21 (0%) | 4/21 (19%) | 16/21 (76.2%) |
| Maintenance Period: Miri IR - 200 mg Miri SC - ME2 Cohort | 0/52 (0%) | 7/52 (13.5%) | 32/52 (61.5%) |
| Maintenance Period: PBO IR - PBO SC - ME2 Cohort | 0/12 (0%) | 1/12 (8.3%) | 10/12 (83.3%) |
| LOR Rescue Period: LOR Cohort-300 mg Miri IV | 0/90 (0%) | 3/90 (3.3%) | 18/90 (20%) |
| LOR Rescue Period: LOR Cohort-300 mg Miri IV - ME2 Cohort | 0/12 (0%) | 2/12 (16.7%) | 4/12 (33.3%) |
| Extended Induction: Induction Nonresponders - 300mg Miri IV | 0/461 (0%) | 24/461 (5.2%) | 74/461 (16.1%) |
| Extended Induction: Induction Nonresponders - 300mg Miri IV - ME2 Cohort | 0/66 (0%) | 4/66 (6.1%) | 22/66 (33.3%) |
| Open Label Maintenance: Delayed Responders - 200 mg Miri SC | 0/271 (0%) | 9/271 (3.3%) | 91/271 (33.6%) |
| Open Label Maintenance: Delayed Responders - 200 mg Miri SC - ME2 Cohort | 0/33 (0%) | 3/33 (9.1%) | 13/33 (39.4%) |
| Event | Maintenance Period: Miri IR - PBO SC | Maintenance Period: Miri IR - 200 mg Miri SC | Maintenance Period: PBO IR - PBO SC | Maintenance Period: Miri IR - PBO SC - ME2 Cohort | Maintenance Period: Miri IR - 200 mg Miri SC - ME2 Cohort | Maintenance Period: PBO IR - PBO SC - ME2 Cohort | LOR Rescue Period: LOR Cohort-300 mg Miri IV | LOR Rescue Period: LOR Cohort-300 mg Miri IV - ME2 Cohort | Extended Induction: Induction Nonresponders - 300mg Miri IV | Extended Induction: Induction Nonresponders - 300mg Miri IV - ME2 Cohort | Open Label Maintenance: Delayed Responders - 200 mg Miri SC | Open Label Maintenance: Delayed Responders - 200 mg Miri SC - ME2 Cohort |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Colitis ulcerativeGastrointestinal disorders | 7/192 | 0/389 | 1/135 | 1/21 | 1/52 | 0/12 | 1/90 | 1/12 | 9/461 | 2/66 | 3/271 | 2/33 |
| Ankle fractureInjury, poisoning and procedural complications | 0/192 | 0/389 | 0/135 | 0/21 | 0/52 | 1/12 | 0/90 | 0/12 | 0/461 | 0/66 | 0/271 | 0/33 |
| Colorectal adenomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/192 | 0/389 | 0/135 | 0/21 | 0/52 | 0/12 | 0/90 | 1/12 | 0/461 | 0/66 | 0/271 | 0/33 |
| Inguinal herniaGastrointestinal disorders | 0/192 | 1/389 | 0/135 | 1/21 | 0/52 | 0/12 | 0/90 | 0/12 | 0/461 | 0/66 | 0/271 | 0/33 |
| Clostridium difficile infectionInfections and infestations | 0/192 | 0/389 | 0/135 | 1/21 | 0/52 | 0/12 | 0/90 | 0/12 | 0/461 | 0/66 | 0/271 | 0/33 |
| HeadacheNervous system disorders | 0/192 | 0/389 | 0/135 | 1/21 | 0/52 | 0/12 | 0/90 | 0/12 | 0/461 | 0/66 | 0/271 | 0/33 |
| Anal abscessInfections and infestations | 0/192 | 0/389 | 0/135 | 0/21 | 0/52 | 0/12 | 0/90 | 0/12 | 0/461 | 0/66 | 0/271 | 1/33 |
| Human chorionic gonadotropin increasedInvestigations | 0/192 | 0/389 | 0/135 | 0/21 | 0/52 | 0/12 | 0/90 | 0/12 | 0/461 | 0/66 | 0/271 | 1/33 |
| UreterolithiasisRenal and urinary disorders | 0/192 | 0/389 | 0/135 | 0/21 | 0/52 | 0/12 | 0/90 | 0/12 | 1/461 | 0/66 | 0/271 | 1/33 |
| GastritisGastrointestinal disorders | 0/192 | 0/389 | 0/135 | 0/21 | 1/52 | 0/12 | 0/90 | 0/12 | 0/461 | 0/66 | 0/271 | 0/33 |
| Event | Maintenance Period: Miri IR - PBO SC | Maintenance Period: Miri IR - 200 mg Miri SC | Maintenance Period: PBO IR - PBO SC | Maintenance Period: Miri IR - PBO SC - ME2 Cohort | Maintenance Period: Miri IR - 200 mg Miri SC - ME2 Cohort | Maintenance Period: PBO IR - PBO SC - ME2 Cohort | LOR Rescue Period: LOR Cohort-300 mg Miri IV | LOR Rescue Period: LOR Cohort-300 mg Miri IV - ME2 Cohort | Extended Induction: Induction Nonresponders - 300mg Miri IV | Extended Induction: Induction Nonresponders - 300mg Miri IV - ME2 Cohort | Open Label Maintenance: Delayed Responders - 200 mg Miri SC | Open Label Maintenance: Delayed Responders - 200 mg Miri SC - ME2 Cohort |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Colitis ulcerativeGastrointestinal disorders | 35/192 | 26/389 | 17/135 | 6/21 | 4/52 | 3/12 | 0/90 | 0/12 | 4/461 | 1/66 | 10/271 | 1/33 |
| Upper respiratory tract infectionInfections and infestations | 5/192 | 7/389 | 2/135 | 4/21 | 8/52 | 1/12 | 1/90 | 0/12 | 3/461 | 6/66 | 9/271 | 4/33 |
| AnaemiaBlood and lymphatic system disorders | 9/192 | 8/389 | 8/135 | 3/21 | 2/52 | 2/12 | 5/90 | 0/12 | 7/461 | 4/66 | 9/271 | 1/33 |
| Covid-19Infections and infestations | 4/192 | 8/389 | 5/135 | 3/21 | 6/52 | 1/12 | 1/90 | 1/12 | 4/461 | 4/66 | 6/271 | 1/33 |
| Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/78 | 0/160 | 0/61 | 0/6 | 0/23 | 0/5 | 0/43 | 0/7 | 0/166 | 0/18 | 0/111 | 1/7 |
| Clostridium difficile infectionInfections and infestations | 3/192 | 1/389 | 1/135 | 2/21 | 0/52 | 0/12 | 2/90 | 0/12 | 4/461 | 3/66 | 3/271 | 1/33 |
| Alanine aminotransferase increasedInvestigations | 1/192 | 4/389 | 1/135 | 2/21 | 1/52 | 0/12 | 1/90 | 0/12 | 0/461 | 2/66 | 0/271 | 0/33 |
| Aspartate aminotransferase increasedInvestigations | 0/192 | 3/389 | 0/135 | 2/21 | 1/52 | 0/12 | 1/90 | 0/12 | 1/461 | 1/66 | 1/271 | 0/33 |
| HypoalbuminaemiaMetabolism and nutrition disorders | 0/192 | 0/389 | 0/135 | 2/21 | 1/52 | 0/12 | 0/90 | 1/12 | 0/461 | 0/66 | 0/271 | 0/33 |
| HypokalaemiaMetabolism and nutrition disorders | 0/192 | 2/389 | 0/135 | 2/21 | 0/52 | 1/12 | 1/90 | 0/12 | 1/461 | 4/66 | 0/271 | 1/33 |
All randomized participants.
| Age, Continuous(years) | Maintenance Period: Miri IR - PBO SC | Maintenance Period: Miri IR - 200 mg Miri SC | Maintenance Period: PBO IR - PBO SC | Maintenance Period: Miri IR - PBO SC - ME2 Cohort | Maintenance Period: Miri IR - 200 mg Miri SC - ME2 Cohort | Maintenance Period: PBO IR - PBO SC - ME2 Cohort | Extended Induction: Induction Nonresponders - 300mg Miri IV | Extended Induction: Induction Nonresponders - 300mg Miri IV - ME2 Cohort | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 41.20 ± 12.88 | 43.30 ± 14.13 | 40.80 ± 13.40 | 49.10 ± 10.71 | 42.50 ± 13.90 | 56.20 ± 14.01 | 43.40 ± 13.86 | 44.40 ± 14.82 | 43.0 ± 13.85 |
| Sex: Female, Male(Participants) | Maintenance Period: Miri IR - PBO SC | Maintenance Period: Miri IR - 200 mg Miri SC | Maintenance Period: PBO IR - PBO SC | Maintenance Period: Miri IR - PBO SC - ME2 Cohort | Maintenance Period: Miri IR - 200 mg Miri SC - ME2 Cohort | Maintenance Period: PBO IR - PBO SC - ME2 Cohort | Extended Induction: Induction Nonresponders - 300mg Miri IV | Extended Induction: Induction Nonresponders - 300mg Miri IV - ME2 Cohort | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 78 | 160 | 61 | 6 | 23 | 5 | 166 | 18 | 517 |
| Male | 114 | 229 | 74 | 15 | 29 | 7 | 295 | 48 | 811 |
| Ethnicity (NIH/OMB)(Participants) | Maintenance Period: Miri IR - PBO SC | Maintenance Period: Miri IR - 200 mg Miri SC | Maintenance Period: PBO IR - PBO SC | Maintenance Period: Miri IR - PBO SC - ME2 Cohort | Maintenance Period: Miri IR - 200 mg Miri SC - ME2 Cohort | Maintenance Period: PBO IR - PBO SC - ME2 Cohort | Extended Induction: Induction Nonresponders - 300mg Miri IV | Extended Induction: Induction Nonresponders - 300mg Miri IV - ME2 Cohort | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 2 | 12 | 2 | 0 | 0 | 0 | 11 | 0 | 27 |
| Not Hispanic or Latino | 18 | 33 | 8 | 0 | 0 | 0 | 53 | 0 | 112 |
| Unknown or Not Reported | 172 | 344 | 125 | 21 | 52 | 12 | 397 | 66 | 1189 |
| Race (NIH/OMB)(Participants) | Maintenance Period: Miri IR - PBO SC | Maintenance Period: Miri IR - 200 mg Miri SC | Maintenance Period: PBO IR - PBO SC | Maintenance Period: Miri IR - PBO SC - ME2 Cohort | Maintenance Period: Miri IR - 200 mg Miri SC - ME2 Cohort | Maintenance Period: PBO IR - PBO SC - ME2 Cohort | Extended Induction: Induction Nonresponders - 300mg Miri IV | Extended Induction: Induction Nonresponders - 300mg Miri IV - ME2 Cohort | Total |
|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 3 | 2 | 0 | 0 | 0 | 4 | 0 | 10 |
| Asian | 51 | 93 | 28 | 21 | 52 | 12 | 87 | 66 | 410 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Black or African American | 0 | 6 | 0 | 0 | 0 | 0 | 6 | 0 | 12 |
| White | 138 | 285 | 103 | 0 | 0 | 0 | 358 | 0 | 884 |
| More than one race | 0 | 0 | 2 | 0 | 0 | 0 | 1 | 0 | 3 |
| Unknown or Not Reported | 2 | 2 | 0 | 0 | 0 | 0 | 4 | 0 | 8 |
| Region of Enrollment(Participants) | Maintenance Period: Miri IR - PBO SC | Maintenance Period: Miri IR - 200 mg Miri SC | Maintenance Period: PBO IR - PBO SC | Maintenance Period: Miri IR - PBO SC - ME2 Cohort | Maintenance Period: Miri IR - 200 mg Miri SC - ME2 Cohort | Maintenance Period: PBO IR - PBO SC - ME2 Cohort | Extended Induction: Induction Nonresponders - 300mg Miri IV | Extended Induction: Induction Nonresponders - 300mg Miri IV - ME2 Cohort | Total |
|---|---|---|---|---|---|---|---|---|---|
| China | 3 | 4 | 1 | 21 | 52 | 12 | 7 | 66 | 166 |
| Argentina | 1 | 5 | 0 | 0 | 0 | 0 | 5 | 0 | 11 |
| Australia | 0 | 3 | 0 | 0 | 0 | 0 | 9 | 0 | 12 |
| Austria | 2 | 2 | 0 | 0 | 0 | 0 | 4 | 0 | 8 |
| Belgium | 1 | 2 | 2 | 0 | 0 | 0 | 4 | 0 | 9 |
| Canada | 3 | 5 | 2 | 0 | 0 | 0 | 21 | 0 | 31 |
| Czechia | 7 | 19 | 11 | 0 | 0 | 0 | 15 | 0 | 52 |
| Denmark | 3 | 3 | 0 | 0 | 0 | 0 | 1 | 0 | 7 |
| France | 10 | 18 | 6 | 0 | 0 | 0 | 23 | 0 | 57 |
| Germany | 5 | 13 | 3 | 0 | 0 | 0 | 16 | 0 | 37 |
| Hungary | 1 | 8 | 2 | 0 | 0 | 0 | 12 | 0 | 23 |
| India | 18 | 25 | 16 | 0 | 0 | 0 | 13 | 0 | 72 |
| Ireland | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Israel | 3 | 6 | 1 | 0 | 0 | 0 | 5 | 0 | 15 |
| Italy | 3 | 12 | 4 | 0 | 0 | 0 | 17 | 0 | 36 |
| Japan | 25 | 47 | 8 | 0 | 0 | 0 | 43 | 0 | 123 |
| Latvia | 8 | 10 | 3 | 0 | 0 | 0 | 8 | 0 | 29 |
| Lithuania | 6 | 4 | 5 | 0 | 0 | 0 | 7 | 0 | 22 |
| Malaysia | 0 | 3 | 0 | 0 | 0 | 0 | 3 | 0 | 6 |
| Mexico | 1 | 3 | 2 | 0 | 0 | 0 | 4 | 0 | 10 |
| Netherlands | 1 | 6 | 0 | 0 | 0 | 0 | 3 | 0 | 10 |
| Poland | 15 | 32 | 13 | 0 | 0 | 0 | 62 | 0 | 122 |
| Romania | 4 | 2 | 0 | 0 | 0 | 0 | 8 | 0 | 14 |
| Russia | 19 | 36 | 16 | 0 | 0 | 0 | 29 | 0 | 100 |
| Serbia | 1 | 9 | 4 | 0 | 0 | 0 | 7 | 0 | 21 |
| Slovakia | 6 | 7 | 1 | 0 | 0 | 0 | 7 | 0 | 21 |
| South Korea | 3 | 8 | 1 | 0 | 0 | 0 | 13 | 0 | 25 |
| Spain | 1 | 6 | 4 | 0 | 0 | 0 | 9 | 0 | 20 |
| Switzerland | 0 | 4 | 0 | 0 | 0 | 0 | 6 | 0 | 10 |
| Taiwan | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 3 |
| Turkey | 0 | 5 | 2 | 0 | 0 | 0 | 1 | 0 | 8 |
| Ukraine | 18 | 31 | 16 | 0 | 0 | 0 | 28 | 0 | 93 |
| United Kingdom | 2 | 4 | 2 | 0 | 0 | 0 | 6 | 0 | 14 |
| United States | 21 | 45 | 10 | 0 | 0 | 0 | 64 | 0 | 140 |
Showing the first 100 of 385 sites across 34 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Oct 2018 to primary completion in Nov 2021, 36 months.
Results were first posted in Nov 2022, 1 year after primary completion.
Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's 36 months is below that.
Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mirikizumab